Drug shortages homepage
Welcome to Drug Shortages Canada, the website for mandatory reporting of drug shortages and discontinuations by market authorization holders. Anyone can search the database of shortage and discontinuation reports. More information can be found on the About & Resources Page.
Early reporting of shortages and discontinuations provides Health Canada, provincial/territorial governments, drug supply chain stakeholders, and health professionals details needed to help them monitor and manage supply. Shortages can be caused by many factors. Some last longer and are more complex than others. Because companies have to report every time they cannot fully meet demand, not all of the reports on this site are cause for concern at the patient level. Most are successfully managed before they impact patients.
The shortage database has a flag that indicates ones that are Tier 3 drug shortages, which are those that could potentially have the highest impact on Canada's drug supply and health care system. A Tier 3 designation is decided by the Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders.
Ensuring people can get the medicines they need is a top priority for Health Canada. Health Canada works closely with many partners to prevent shortages, mitigate their impacts, and help resolve them when they occur.
If you would like to know more about shortages like why they happen, how long they last, the actions being taken to reduce impacts on Canadians, and actions you can take if a drug you use is in shortage, please consult the information on Canada.ca.
Below are the newest shortage and discontinuation reports and updates to existing ones.
LEGEND
!!T3 denotes an actual Tier 3 shortage/discontinuation
!T3 denotes an anticipated Tier 3 shortage/discontinuation
Shortage Reports
Brand name | Company Name | Status | Strength | Update | Date Updated | View Report |
---|---|---|---|---|---|---|
SODIUM ACETATE INJECTION USP | OMEGA LABORATORIES LIMITED | Actual shortage | 328MG | Updated Report | 2024-12-10 | 245319 |
AURO-TRAMADOL | AURO PHARMA INC | Actual shortage | 50MG | Updated Report | 2024-12-10 | 242984 |
!!T3 HYDRALAZINE HYDROCHLORIDE INJECTION, USP | EUGIA PHARMA INC. | Actual shortage | 20MG | Updated Report | 2024-12-10 | 241496 |
PHENOBARB ELIXIR | PENDOPHARM DIVISION OF PHARMASCIENCE INC | Actual shortage | 5MG | Updated Report | 2024-12-10 | 232926 |
DIAMICRON MR | SERVIER CANADA INC | Actual shortage | 30MG | New Report | 2024-12-10 | 245310 |
VORANIGO | SERVIER CANADA INC | Actual shortage | 10MG | New Report | 2024-12-10 | 245307 |
VINBLASTINE SULPHATE INJECTION | TEVA CANADA LIMITED | Anticipated shortage | 1MG | New Report | 2024-12-10 | 245304 |
ALLERGENIC EXTRACT NON POLLENS | ALK-ABELLO INC | Actual shortage | 100000UNIT | Updated Report | 2024-12-10 | 201856 |
ALLERGENIC EXTRACT NON POLLENS | ALK-ABELLO INC | Actual shortage | 100000UNIT | Updated Report | 2024-12-10 | 204072 |
HISTATROL | ALK-ABELLO INC | Actual shortage | 0.275MG | Updated Report | 2024-12-10 | 173325 |
HISTATROL | ALK-ABELLO INC | Actual shortage | 2.75MG | Updated Report | 2024-12-10 | 173322 |
THALLOUS CHLORIDE TI-201 INJECTION | CURIUM CANADA INC | Actual shortage | 37MBq | Updated Report | 2024-12-10 | 171882 |
LABETALOL HYDROCHLORIDE INJECTION, USP | MYLAN PHARMACEUTICALS ULC | Resolved | 5MG | Updated Report | 2024-12-10 | 78454 |
TEVETEN PLUS | BGP PHARMA ULC | Resolved | 12.5MG 600MG | Updated Report | 2024-12-10 | 169169 |
TEVETEN | BGP PHARMA ULC | Resolved | 400MG | Updated Report | 2024-12-10 | 171165 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | Actual shortage | 4.5MG | Updated Report | 2024-12-10 | 234493 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | Actual shortage | 4.5MG | Updated Report | 2024-12-10 | 237768 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | Actual shortage | 3MG | Updated Report | 2024-12-10 | 237764 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | Actual shortage | 1.5MG | Updated Report | 2024-12-10 | 230768 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | Actual shortage | 1.5MG | Updated Report | 2024-12-10 | 235071 |
Discontinuation Reports
Brand name | Company Name | Status | Strength | Update | Date Updated | View Report |
---|---|---|---|---|---|---|
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | To be discontinued | 6MG | New Report | 2024-12-10 | 245291 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | To be discontinued | 1.5MG | New Report | 2024-12-10 | 245288 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | To be discontinued | 1.5MG | New Report | 2024-12-10 | 245285 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | To be discontinued | 4.5MG | New Report | 2024-12-10 | 245282 |
SANDOZ RIVASTIGMINE | SANDOZ CANADA INCORPORATED | To be discontinued | 4.5MG | New Report | 2024-12-10 | 245279 |